USNA vs. CRON, MNMD, CGC, BTMD, ACB, CDXC, AORT, OPK, ARCT, and RGNX
Should you be buying USANA Health Sciences stock or one of its competitors? The main competitors of USANA Health Sciences include Cronos Group (CRON), Mind Medicine (MindMed) (MNMD), Canopy Growth (CGC), biote (BTMD), Aurora Cannabis (ACB), ChromaDex (CDXC), Artivion (AORT), OPKO Health (OPK), Arcturus Therapeutics (ARCT), and REGENXBIO (RGNX). These companies are all part of the "medical" sector.
Cronos Group (NASDAQ:CRON) and USANA Health Sciences (NYSE:USNA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, community ranking, profitability, valuation, media sentiment, analyst recommendations, earnings, risk and institutional ownership.
In the previous week, Cronos Group had 1 more articles in the media than USANA Health Sciences. MarketBeat recorded 5 mentions for Cronos Group and 4 mentions for USANA Health Sciences. USANA Health Sciences' average media sentiment score of 0.50 beat Cronos Group's score of 0.44 indicating that Cronos Group is being referred to more favorably in the media.
USANA Health Sciences has a net margin of 6.93% compared to USANA Health Sciences' net margin of -84.15%. Cronos Group's return on equity of 13.49% beat USANA Health Sciences' return on equity.
Cronos Group received 69 more outperform votes than USANA Health Sciences when rated by MarketBeat users. Likewise, 61.21% of users gave Cronos Group an outperform vote while only 60.77% of users gave USANA Health Sciences an outperform vote.
USANA Health Sciences has higher revenue and earnings than Cronos Group. Cronos Group is trading at a lower price-to-earnings ratio than USANA Health Sciences, indicating that it is currently the more affordable of the two stocks.
Cronos Group presently has a consensus target price of $2.83, indicating a potential upside of 8.56%. USANA Health Sciences has a consensus target price of $48.00, indicating a potential upside of 10.47%. Given Cronos Group's stronger consensus rating and higher probable upside, analysts plainly believe USANA Health Sciences is more favorable than Cronos Group.
8.7% of Cronos Group shares are owned by institutional investors. Comparatively, 54.3% of USANA Health Sciences shares are owned by institutional investors. 2.0% of Cronos Group shares are owned by company insiders. Comparatively, 0.3% of USANA Health Sciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Cronos Group has a beta of 1.17, indicating that its stock price is 17% more volatile than the S&P 500. Comparatively, USANA Health Sciences has a beta of 0.91, indicating that its stock price is 9% less volatile than the S&P 500.
Summary
USANA Health Sciences beats Cronos Group on 10 of the 18 factors compared between the two stocks.
Get USANA Health Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for USNA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding USNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
USANA Health Sciences Competitors List
Related Companies and Tools
